Observational studyEuropean journal of haematology2025

Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine.

Steffen Koschmieder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.